10-Q: Abbott Reports Strong Q3 Sales, Medical Devices Lead Growth

Abbott Laboratories reported a 6.9% increase in net sales for the third quarter of 2025, driven by robust performance in its Medical Devices segment, despite a decline in COVID-19 testing sales.

Summary

• Net sales for the third quarter of 2025 increased 6.9% to $11.369 billion, or 5.5% excluding the impact of foreign exchange, compared to the prior year.
• Net sales for the first nine months of 2025 increased 6.1% to $32.869 billion, or 6.4% excluding the impact of foreign exchange, compared to the prior year.
• Operating earnings for the third quarter of 2025 grew 10.7% to $2.057 billion, and for the first nine months, increased 18.1% to $5.802 billion.
• Net earnings for the third quarter of 2025 were $1.644 billion, slightly down from $1.646 billion in Q3 2024, while nine-month net earnings rose 13.8% to $4.748 billion.
• Diluted Earnings Per Common Share remained flat at $0.94 for Q3 2025 but increased 13.4% to $2.70 for the first nine months of 2025.
• Gross profit margin improved to 51.7% in Q3 2025 (from 51.4% in Q3 2024) and to 52.4% for the first nine months (from 51.0% in 2024).
• Medical Devices sales, excluding foreign exchange, increased 12.4% for the first nine months of 2025, led by double-digit growth in Diabetes Care, Heart Failure, Structural Heart, and Electrophysiology.
• COVID-19 testing-related sales declined significantly to $69 million in Q3 2025 (from $265 million in Q3 2024) and $208 million for the first nine months (from $571 million in 2024).
• Restructuring plans initiated in 2025 resulted in $197 million in employee-related severance and other charges and $25 million in asset impairment charges for the first nine months.
• Repaid $1.5 billion in long-term debt maturities in March and September 2025.
• The board authorized a new $7 billion share repurchase program in October 2024, in addition to the unused portion of a prior program.
• The quarterly dividend increased by 7.3% to $0.59 per share.

Sentiment

Score: 8

Explanation: The company demonstrated strong sales and operating earnings growth, particularly in its Medical Devices segment, and improved gross margins. The dividend increase and new share repurchase program reflect financial strength. While there are ongoing legal and tax challenges, management expresses confidence in their positions. The decline in COVID-19 testing sales is a known factor, and other segments are performing well to offset this.

Positives

• Strong overall net sales growth, both total and excluding foreign exchange, for the quarter and nine-month period.
• Significant operating earnings growth for both periods, indicating improved operational efficiency.
• Improved gross profit margins for both the quarter (51.7%) and nine-month period (52.4%).
• Robust performance in the Medical Devices segment, with 12.4% sales growth (excluding foreign exchange) for the nine months, driven by double-digit growth in key areas like Diabetes Care (19.4% growth in continuous glucose monitoring systems sales), Heart Failure (12.9%), Structural Heart (12.5%), and Electrophysiology (11.3%).
• Established Pharmaceutical Products segment showed solid growth of 7.5% (excluding foreign exchange) for the nine months, particularly in Key Emerging Markets (9.7%).
• Nutritional Products sales increased 4.5% (excluding foreign exchange) for the nine months, with strong international adult nutritionals growth (10.2%).
• Successful product approvals and launches in Medical Devices, including CE Mark for Volt Pulsed Field Ablation (PFA) System, FDA approval for Tendyne transcatheter mitral valve replacement (TMVR) system, Japan regulatory approval for TriClip, and expanded CE Mark for Navitor transcatheter aortic valve implantation (TAVI) system.
• Decreased interest expense by $27 million to $143 million for the first nine months of 2025 due to debt repayments.
• Increased quarterly dividend by 7.3% to $0.59 per share.
• Authorization of a new $7 billion share repurchase program, demonstrating commitment to shareholder returns.
• Net cash from operating activities increased by $561 million to $6.251 billion for the first nine months of 2025.

Negatives

• Net earnings for the third quarter of 2025 were flat at $1.644 billion compared to $1.646 billion in Q3 2024.
• Significant decline in COVID-19 testing-related sales, impacting the Diagnostic Products segment (down 18.0% excluding foreign exchange for Rapid Diagnostics).
• Challenging market conditions in China, including volume-based procurement programs, negatively impacted Core Laboratory Diagnostics sales.
• U.S. Adult Nutritionals sales decreased by 0.9% due to lower Ensure product sales and the discontinuation of the ZonePerfect product line.
• Restructuring plans led to $197 million in employee-related severance and other charges and $25 million in asset impairment charges for the first nine months of 2025.
• Taxes on earnings for the first nine months of 2025 include approximately $460 million of tax expense related to a deferred tax asset recognized as a significant non-cash tax benefit in a prior year.

Risks

• Ongoing lawsuits alleging that preterm infant formula and human milk fortifier products cause necrotizing enterocolitis (NEC) and inadequately warn about the risk of NEC. A Missouri state case resulted in a $495 million damages award against Abbott, which is currently on appeal. Management believes the resolution of these cases could be material to financial position, cash flows, or results of operations.
• Uncertainty regarding the outcome of various tax disputes with the IRS, including Statutory Notices of Deficiency (SNODs) totaling $417 million (2019), $192 million (2017/2018), and $443 million (2020) related to income reallocation, which Abbott is contesting.
• Highly competitive primary markets and substantial government regulations throughout the world, which could adversely affect operations.
• Uncertainty regarding future legislative changes concerning healthcare product availability, method of delivery, and payment.
• Impact of foreign currency exchange rate changes on net sales and costs.
• Challenging market conditions in China, including the impact of volume-based procurement programs, affecting Diagnostic Products sales.
• Potential for non-performance by counterparties to financial instruments, although Abbott does not expect losses.
• The need to continuously innovate and launch new products to maintain growth, especially in competitive medical device and diagnostic markets.

Future Outlook

Abbott expects continued debate over healthcare product availability, delivery, and payment. The company is evaluating the impact of new accounting standards (ASU 2024-03 and ASU 2023-09) for future reporting periods. Management intends to vigorously defend its tax filing positions against IRS challenges and continues to monitor OECD Pillar 1 and Pillar 2 developments.

Management Comments

• Management believes that their ultimate disposition [of legal proceedings and environmental exposures] should not have a material adverse effect on Abbott's financial position, cash flows, or results of operations, except for the NEC cases, the resolution of which could be material.
• Abbott believes that the income reallocation adjustments proposed in the SNODs are without merit.
• Abbott intends to vigorously defend its filing positions through ongoing discussions with the IRS, the IRS independent appeals process, and/or through litigation, as necessary.
• Abbott continues to believe that its reserves for uncertain tax positions are appropriate.
• Abbott expects to maintain an investment grade rating.
• Abbott stands by its products and the information it provided about them [regarding NEC lawsuits].

Industry Context

The healthcare industry remains highly competitive and subject to significant government regulation globally. Abbott's strong performance in Medical Devices, particularly in continuous glucose monitoring (CGM) systems, reflects a broader industry trend towards innovative, less invasive medical technologies. The decline in COVID-19 testing sales indicates a normalization of the diagnostics market post-pandemic. Challenges in the Chinese market, including volume-based procurement programs, highlight the evolving regulatory and competitive landscape in key emerging markets for pharmaceutical and diagnostic products.

Corporate Governance

Legal Proceedings

• Abbott is a defendant in numerous lawsuits alleging that its preterm infant formula and human milk fortifier products cause necrotizing enterocolitis (NEC) and inadequately warn about the risk.
• A Missouri state case jury awarded a plaintiff $495 million in damages, which is currently on appeal.
• In a second Missouri state court case, a jury found in Abbott's favor, but the judge later ordered a new trial; this case is also on appeal.
• In the first three federal Multidistrict Litigation (MDL) bellwether cases, the U.S. District Court for the Northern District of Illinois granted summary judgment in favor of Abbott in the second and third cases (August and October 2025), while the plaintiff in the first case has filed an appeal.
• Management believes the ultimate disposition of these NEC lawsuits could be material to Abbott's financial position, cash flows, or results of operations.
• Abbott has been identified as a potentially responsible party for investigation and cleanup costs at various U.S. and Puerto Rico locations, with an aggregate cleanup exposure not expected to exceed $10 million.
• The estimated range of possible loss for other legal proceedings and environmental exposures is $5 million to $15 million, with a recorded accrual balance of approximately $10 million at September 30, 2025.

Stakeholder Impact

• Shareholders: Positive impact from increased dividend, new share repurchase program, and strong sales/earnings growth. Potential negative impact from ongoing legal proceedings (NEC lawsuits) and tax disputes, which could result in material losses or liabilities.
• Employees: Impacted by restructuring plans in diagnostic and medical devices businesses, leading to severance and other charges.
• Customers: Benefit from new product approvals and launches in Medical Devices (e.g., Volt PFA System, Tendyne TMVR, TriClip, Navitor TAVI).
• Creditors: Positive impact from debt repayments and maintenance of investment-grade credit ratings (AAby S&P, Aa3 by Moody's).

Next Steps

• Continue to defend against NEC lawsuits, including appeals in Missouri state cases and the first federal MDL bellwether case.
• Vigorously defend tax filing positions through discussions with the IRS, appeals process, and/or litigation regarding SNODs for 2017-2020 tax years.
• Evaluate the impact of new accounting standards ASU 2024-03 (effective 2027) and ASU 2023-09 (effective 2025) on consolidated financial statements.
• Monitor developments related to OECD Pillar 1 and Pillar 2 international tax proposals.
• Continue to streamline operations in diagnostic and medical devices businesses as part of the 2025 restructuring plan.
• Recognize remaining share-based compensation cost of $577 million over the next three years.
• Continue share repurchases under the October 2024 authorization.

Key Dates

Recommendation

Abbott Laboratories demonstrates robust financial health with strong sales growth, particularly in its high-margin Medical Devices segment, driven by innovative products like continuous glucose monitoring systems. The company's improved operating earnings and gross profit margins indicate effective cost management and operational efficiency. The 7.3% dividend increase and the substantial $7 billion share repurchase authorization signal strong confidence from management in future cash flows and commitment to shareholder returns. While the ongoing NEC lawsuits and IRS tax disputes present potential liabilities, management is vigorously defending its positions, and the core business performance remains compelling. The diversification across pharmaceuticals, nutritionals, diagnostics, and medical devices provides resilience, and the strategic focus on high-growth areas like diabetes care positions the company well for sustained long-term value creation, making it an attractive 'buy' for long-term investors.

Keywords

Abbott Laboratories, ABT, SEC Filing, 10-Q, Quarterly Report, Financial Results, Medical Devices, Diagnostics, Nutritional Products, Established Pharmaceuticals, Diabetes Care, Structural Heart, Electrophysiology, Rhythm Management, COVID-19 Testing, Earnings, Sales Growth, Restructuring, Legal Proceedings, NEC Lawsuits, IRS Tax Disputes, Share Repurchase, Dividend Increase, Healthcare Industry, Financial Performance